🔴 Axsome Therapeutics is trading 4.46% down in pre-market with no confirmed catalyst

Axsome Therapeutics is trading at $137.99, down 4.46% in pre-market; coverage has not identified a specific negative catalyst.

• Before the open on November 2, Axsome reported third-quarter product revenue of $259.7 million, up 52% year over year, and a $0.25-per-share loss; results beat reported estimates.
• Coverage does not establish that earnings caused the pre-market decline.
• Shares closed at $144.43 on October 30, after a 7.07% drop on October 23; November 2 volume was unverified.